23andMe, a Mountain View, CA-based personal genetics company, raised $79m in equity funding.
According to a regulatory filing with the S.E.C., $71m could still be sold with the round totalling to $150m.
The number of investors who already have invested in the offering is 15.
Founded in 2006 by CEO Anne Wojcicki, 23andMe provides a DNA testing and genome sequencing platform for people to access, understand and benefit from the human genome. The company has more than one million customers worldwide, with over 80 percent consented to participate in research, collecting more than 270 million phenotypic data points (individual survey responses).
It is currently driving studies for new disease treatments in collaboration with pharmaceutical and biotechnology companies, and academic institutions.
23and Me had previously raised over $110m from NEA, Google Ventures, Yuri Milner, among others.